Meeting
2021 ASCO Annual Meeting
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
Authors
Yazmin Odia
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Yazmin Odia , Samuel Aaron Goldlust , Minesh P. Mehta , Andrew B. Lassman , Howard Colman , Priya Kumthekar , Warren P. Mason , Rebecca A. Harrison , Nicholas A. Butowski , Vyshak Venur , Scott Randall Plotkin , Michael Schulder , John A Boockvar , J Paul Duic , Kai Li , Yang Liu , Sharon Tamir , Gregory Mundy , Sharon Shacham , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04421378
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2071)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2071
Abstract #
TPS2071
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Digital measurement of functional status of patients with glioblastoma.
First Author: Yasaman Damestani
Poster
2015 ASCO Annual Meeting
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
First Author: Ulrik Niels Lassen
Poster
2022 ASCO Annual Meeting
Mebendazole in recurrent glioblastoma: Results of a phase 2 randomized study.
First Author: Nandini Sharrel Menon
First Author: Yasaman Damestani